Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Moodys
Dow
Harvard Business School
McKesson

Last Updated: September 27, 2022

Angiotensin ii acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for angiotensin ii acetate and what is the scope of patent protection?

Angiotensin ii acetate is the generic ingredient in one branded drug marketed by La Jolla Pharma and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Angiotensin ii acetate has thirty-nine patent family members in twenty-one countries.

One supplier is listed for this compound.

Summary for angiotensin ii acetate
Recent Clinical Trials for angiotensin ii acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kasr El Aini HospitalN/A
American Lung AssociationPhase 2
Johns Hopkins UniversityPhase 2

See all angiotensin ii acetate clinical trials

Pharmacology for angiotensin ii acetate
Drug Class Vasoconstrictor
Physiological EffectVasoconstriction
Medical Subject Heading (MeSH) Categories for angiotensin ii acetate
Paragraph IV (Patent) Challenges for ANGIOTENSIN II ACETATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GIAPREZA Injection angiotensin ii acetate 2.5 mg/mL 209360 1 2021-12-21

US Patents and Regulatory Information for angiotensin ii acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-003 Dec 23, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-002 Dec 21, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for angiotensin ii acetate

Country Patent Number Title Estimated Expiration
Israel 246162 אנגיוטנסין ii, לבד או בשילוב, לטיפול בלחץ דם נמוך (Angiotensin ii alone or in combination for the treatment of hypotension) See Plans and Pricing
Japan 2019214610 低血圧治療のための単独または併用使用されるアンギオテンシンII (ANGIOTENSIN II ALONE OR IN COMBINATION FOR TREATMENT OF HYPOTENSION) See Plans and Pricing
South Korea 20160117437 저혈압의 치료를 위한 안지오텐신 II 단독 또는 조합 (II ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION) See Plans and Pricing
Australia 2017205168 Methods for administering angiotensin II See Plans and Pricing
Taiwan 201733610 Methods for administering angiotensin II See Plans and Pricing
Japan 2017501154 低血圧治療のための単独または併用使用されるアンギオテンシンII See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Dow
Mallinckrodt
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.